$MRNA, $ALNY, $BGNE, $LEGN, $RPRX, $ROIV fell by 5-8% over the week.
Over the past week, the stock market has continued to decline. Leading the decline are biotechnology company stocks, which have fallen by 5-8%. You can receive signals for these company stocks by subscribing to our robots: Swing-trader-Downtrend-Protection-v-2-TA.
Notable Companies
Some of the most prominent companies in the Biotechnology industry include:
- Regeneron Pharmaceuticals (NASDAQ: REGN)
- Moderna (NASDAQ: MRNA)
- Incyte Corp (NASDAQ: INCY)
- Sarepta Therapeutics (NASDAQ: SRPT)
- Exelixis (NASDAQ: EXEL)
- Arrowhead Pharmaceuticals (NASDAQ: ARWR)
- BioCryst Pharmaceuticals (NASDAQ: BCRX)
- Adaptive Biotechnologies Corp (NASDAQ: ADPT)
- Novavax (NASDAQ: NVAX)
- Sorrento Therapeutics (OTC: SRNEQ)
Industry Description
Biotechnology is a diverse field that involves genetic and protein engineering to develop medications and therapies for the treatment and prevention of various medical conditions. Additionally, the industry plays a crucial role in producing essential components for diagnostic purposes. It's a multi-billion-dollar industry with a strong focus on research and development to innovate cutting-edge healthcare solutions.
Discoveries in the biotechnology sector have the potential for substantial growth. However, these breakthroughs must undergo rigorous regulatory approval processes, often by the U.S. Food and Drug Administration (FDA), before they can be introduced to the market. Some well-known companies in this industry include Amgen Inc., Gilead Sciences, Inc., and Celgene Corporation.
Market Capitalization
The average market capitalization within the Biotechnology industry is approximately $2.2 billion. Companies in this sector exhibit a wide range of market capitalization, spanning from $402 million to $410.2 billion. Notably, NVO holds the highest valuation in this group at $410.2 billion, while the lowest valued company is PNEXF at $402 million.
High and Low Price Notable News
Price fluctuations in the Biotechnology industry are quite dynamic. The average weekly price movement across all stocks in this sector was -3.83%. Over a monthly period, the average price growth was more positive at 22.16%, and for a quarter, it further increased to 34.16%. Among individual stocks, RNAZ experienced remarkable price growth at 335.08%, while SEEL faced a significant decline of -80.84%.
Some recent price highlights include:
- On 9/6/23 at 7:51 AM, Moderna (MRNA, $109.36) experienced a weekly decline of -5.72%, potentially indicating a trend reversal.
- On 8/25/23 at 7:08 AM, Moderna (MRNA, $112.65) showed a substantial weekly gain of +6.03%, suggesting a potential continuation of an uptrend.
- On 8/18/23 at 11:29 AM, Moderna (MRNA, $106.24) recorded a significant weekly gain of +5.94%.
Volume
The trading volume in the Biotechnology Industry is subject to fluctuations. On average, there was a weekly volume growth of 62.71% across all stocks in the industry. Over a month, the average volume growth was 135.64%, and for a quarter, it was 125.83%.
Some notable volume events include:
- On 9/16/23 at 7:44 AM, the volume for Roivant Sciences stock surged for one day, resulting in an extraordinary daily growth of 315% compared to the 65-Day Volume Moving Average.
- On 6/21/23 at 2:33 PM, Royalty Pharma's stock witnessed a consistent increase in volume for five consecutive days, with an average daily gain of 104%.
Fundamental Analysis Ratings
Fundamental analysis ratings help assess the overall health and performance of companies in the industry. These ratings are on a scale from 1 (best) to 100 (worst) and are as follows:
- Valuation Rating: 50
- P/E Growth Rating: 87
- Price Growth Rating: 69
- SMR Rating: 93
- Profit Risk Rating: 95
- Seasonality Score: -24 (on a scale of -100 to +100)
MRNA sees MACD Histogram crosses below signal line on September 19, 2023. This is a bearish signal, with an 85% chance of a downward move.
ALNY: The 10-day Moving Average crossed above the 50-day moving average on September 01, 2023, suggesting a 78% chance of an upward trend continuation.
BGNE: Broke above its upper Bollinger Band on August 29, 2023, indicating a 90% chance of a subsequent drop.
LEGN moved below its 50-day Moving Average on September 05, 2023, signaling a 90% chance of a continued downward trend.
RPRX: The Aroon Indicator entered a downward trend on September 15, 2023, with a 73% chance of a stock decline.
ROIV: The 10-day RSI Indicator moved out of overbought territory on September 11, 2023, implying a 78% chance of a downward trend.
MRNA in downward trend: price expected to drop as it breaks its higher Bollinger Band on February 19, 2026
MRNA broke above its upper Bollinger Band on February 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 41 similar instances where the stock broke above the upper band. In of the 41 cases the stock fell afterwards. This puts the odds of success at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for MRNA moved out of overbought territory on March 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 53 cases where MRNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on February 17, 2026. You may want to consider a long position or call options on MRNA as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on February 19, 2026. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.556) is normal, around the industry mean (30.245). P/E Ratio (0.000) is within average values for comparable stocks, (40.902). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.820). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (11.325) is also within normal values, averaging (315.809).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative medicines for patients
Industry Biotechnology
Advertisement